44843-89-2

Usage

Uses

Used in Pharmaceutical Industry:
5-Hydroxyhexanoic acid is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of drugs targeting specific medical conditions.
Used in Cosmetic Industry:
5-Hydroxyhexanoic acid is used as an active ingredient in the cosmetic industry, particularly in skincare products. Its properties make it suitable for improving skin hydration, promoting skin health, and potentially offering anti-aging benefits.
Used in Chemical Synthesis:
5-Hydroxyhexanoic acid is used as a building block in the synthesis of various chemicals and materials. Its unique structure can be utilized to create novel compounds with specific properties for use in different applications.
Used in Research and Development:
5-Hydroxyhexanoic acid is used as a research tool in the development of new drugs, materials, and technologies. Its unique properties make it an interesting candidate for studying various biological and chemical processes.
Used in Biotechnology:
5-Hydroxyhexanoic acid can be used in biotechnological applications, such as the production of bio-based materials or the development of new biocatalytic processes. Its unique structure can be exploited to create innovative solutions in the field of biotechnology.

InChI:InChI=1/C6H12O3/c1-5(7)3-2-4-6(8)9/h5,7H,2-4H2,1H3,(H,8,9)

Upstream product

• 3128-06-1 5-ketohexanoic acid 

Downstream Products

• 43112-32-9 (R)-(+)-δ-methyl-δ-valerolactone 
• 16320-13-1 (S)-6-methyl-tetrahydro-pyran-2-one 

Relevant academic research and scientific papers

Chain terminators, the use thereof for nucleic acid sequencing and synthesis and a method of their preparation

The invention relates to compounds of general structure (I) or salts thereof, wherein B is a nucleobase, X and Z independently are oxygen or sulphur, Y is hydrogen or hydroxy, which optionally may be protected, R1 is hydrocarbyl, which optionally is substituted with a functional group, R2 is hydrogen or hydrocarbyl, which optionally is substituted with a functional group, A is an electron withdrawing or electron donating group capable of moderating the acetal stability of compound (I), L1 and L2 are hydrocarbon linkers, which may be the same or different, L2, when present, being either (i) connected to L1 via the group A, or (ii) directly connected to L1, the group A then being connected to one of linkers L1 and L2, F is a dye label, Q is a coupling group for F, and l, m and n independently are 0 or 1, with the proviso that l is 1 when m is 1, and l is 1 and m is 1 when n is 1. The compounds of formula (I) are useful as deactivatable chain extension terminators. The invention also relates to the use of the compounds (I) in nucleic acid synthesis and nucleic acid sequencing as well as to a method of preparing compounds of Formula (I).

PHA E and PHA C components of poly(hydroxy fatty acid) synthase from thiocapsa pfennigii

PCT No. PCT/DE95/01279 Sec. 371 Date Jul. 3, 1997 Sec. 102(e) Date Jul. 3, 1997 PCT Filed Sep. 15, 1995 PCT Pub. No. WO96/08566 PCT Pub. Date Mar. 21, 1996The present invention relates to a process for the production of poly (hydroxy fatty acids) as well as recombinant bacterial strains for carrying out the process. In addition, new poly(hydroxy fatty acids) and new substrates for the production of conventional and new poly(hydroxy fatty acids) are described. Moreover, the invention also relates to a DNA fragment, which codes for a PhaE and a PhaC component of the poly(hydroxy fatty acid) synthase from Thiocapsa pfennigii, as well as the corresponding poly (hydroxy fatty acid) synthase protein.

Identification of 5-hydroxyhexanoic acid in the urine of twin siblings with a Reye's-like syndrome associated with dicarboxylic aciduria and hypoglycaemia and with similarities to Jamaican vomiting sickness

Twin male infant siblings who presented in Harrow, UK, with a Reye's-like syndrome associated with profound hypoglycaemia, vomiting, diarrhoea, coma and death in one child, with dicarboxylic aciduria, and similarities to Jamaican vomiting sickness (hypoglycin toxicity) have been shown to excrete large amounts of a previously unrecorded urinary organic acid. This has been identified as 5-hydroxyhexanoic acid by gas chromatography mass spectrometry using a synthesized standard. Concentrations observed were 340 and 330 mg g-1 creatinine in the two patients. The metabolic precursor of the urinary acid is suggested to be hex-4-enoic acid, a probable chemical toxin closely related to the active organic acid metabolite of hypoglycin. The possibility of ω-1 oxidation of hexanoic acid to 5-hydroxyhexanoic acid in these and other patients with dicarboxylic acidurias is also discussed.

Process for the preparation of mixture consisting predominantly of εα-formylvaleric acid and the esters of these acids

A process for preparing a mixture of organic carboxylic acids and esters thereof consisting predominantly of epsilon-hydroxycaproic acid, adipic acid, formylvaleric acid, and esters of these acids by oxidizing a mixture of cyclohexane, cyclohexanol and cyclohexanone with molecular oxygen, which comprises withdrawing at least a part of the oxidation reaction mixture from the oxidation reaction system, extracting the organic carboxylic acids and esters thereof from the oxidation reaction mixture until the concentration of the total carboxyl groups of said oxidation reaction mixture is reduced to a value not greater than 1.2 gram equivalents per liter of the reaction mixture, the several ester bonds of the esters contained in reaction mixture being considered to be carboxyl groups, recycling to the oxidation reaction system the resulting liquid extraction residue containing unreacted cyclohexane, cyclohexanol and cyclohexanone and carrying out the oxidation reaction, while recovering the carboxylic acids and esters thereof from the liquid extract.